Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 31, 2013

View Archived Issues

Generation of a humanized mouse model to study the whole life cycle of HCV

ViaCyte granted over 20 patents in 2013

AEOL-10150 improves survival in mice exposed to lethal radiation

Pipeline developments at AbbVie in third quarter 2013

Lorus Therapeutics to develop LOR-253 for AML and other hematologic cancers

GlaxoSmithKline offers overview of third quarter 2013

Fast clinical responses seen with clazakizumab in patients with rheumatoid arthritis

Phase I trial results support further development of SAN-300 for rheumatoid arthritis

Amgen reports phase I data for AMG-557 in patients with SLE

Activity of neuromuscular blocking agent CW-1759-50 described in monkeys

Chinese scientists prepare new multifunctional antibodies for cancer

Novel naphthyridine derivatives disclosed by Jiangsu Simcere Pharmaceutical R&D

New serotonin 5-HT reuptake inhibitors patented for pain and depression

Researchers at the University of Dundee synthesize novel agents for malaria

Alnylam Pharmaceuticals files CTA to begin phase I study of ALN-AT3

NNZ-2566 receives FDA orphan drug designation in fragile X syndrome

Lantheus Medical Imaging reports results from phase III trial of flurpiridaz F 18

Cempra's Taksta receives FDA orphan drug designation

Merrimack reports results from phase II study of combination therapy for advanced ovarian cancers

KaloBios gains FDA orphan drug status for KB001-A

Janssen submits MAA to EMA for ibrutinib in treatment of two forms of blood cancer

FDA grants orphan drug designations to several drugs for cancer

Eisai files to expand indication for Aricept in Japan

New data reported from extension study of Glassia in pediatric patients with type 1 diabetes

Development of Kremezin discontinued in the U.S. and Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...